Amlodipine

Generic Name
Amlodipine
Brand Names
Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
Drug Type
Small Molecule
Chemical Formula
C20H25ClN2O5
CAS Number
88150-42-9
Unique Ingredient Identifier
1J444QC288
Background

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...

Indication

Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)
...

Associated Conditions
Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
Associated Therapies
-
Clinical Trials
Related News

African American Study of Kidney Disease and Hypertension

First Posted Date
2020-04-27
Last Posted Date
2020-04-27
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
1094
Registration Number
NCT04364139

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

First Posted Date
2020-04-01
Last Posted Date
2024-11-13
Lead Sponsor
Italo Biaggioni
Target Recruit Count
72
Registration Number
NCT04329806
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Calcium Channel Blockade in Primary Aldosteronism

First Posted Date
2019-11-26
Last Posted Date
2024-01-18
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
15
Registration Number
NCT04179019
Locations
🇺🇸

Anand Vaidya, Boston, Massachusetts, United States

Mechanism of Masked Hypertension - Intervention

Phase 3
Withdrawn
Conditions
Masked Hypertension
Interventions
Drug: Carvedilol
Drug: Amlodipine
First Posted Date
2019-10-09
Last Posted Date
2021-11-05
Lead Sponsor
University of Alabama at Birmingham
Registration Number
NCT04121299
Locations
🇺🇸

Hypertension Research Clinic at UAB, Birmingham, Alabama, United States

A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

First Posted Date
2019-08-30
Last Posted Date
2020-11-30
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
145
Registration Number
NCT04074551
Locations
🇰🇷

Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of

Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

First Posted Date
2019-06-07
Last Posted Date
2020-09-03
Lead Sponsor
The University of The West Indies
Registration Number
NCT03978884
Locations
🇯🇲

Tropical Metabolism Research Unit, Kingston, Other, Jamaica

Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension

Not Applicable
Conditions
Hypertension
Interventions
Drug: amlodipine
Drug: telmisartan
First Posted Date
2019-05-21
Last Posted Date
2019-08-08
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
300
Registration Number
NCT03956823
Locations
🇨🇳

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China

The Pharmacokinetic Interaction Between Amlodipine and Losartan

First Posted Date
2019-04-11
Last Posted Date
2019-04-12
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
24
Registration Number
NCT03912285
Locations
🇰🇷

Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

First Posted Date
2019-04-01
Last Posted Date
2022-07-14
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
248
Registration Number
NCT03897868
Locations
🇰🇷

Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

First Posted Date
2019-03-26
Last Posted Date
2019-03-26
Lead Sponsor
IlDong Pharmaceutical Co Ltd
Target Recruit Count
30
Registration Number
NCT03889145
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy